Bruker (BRKR)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$58.50-1.53%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
Broken: Primary pillar broken — Achieve FY2026 non-GAAP EPS of $2.10 to $2.15: FY26 EPS guidance $2.10-$2.15 vs $2.10 target.
Bruker grows revenue about 5% yearly, aiming for $3.57 to $3.60 billion in 2026. Profit margins are expected near 25% to 30%. The company beat Q1 EPS by 35%, showing operational strength. New product launches and semiconductor orders support growth.
Revenue growth is slow at 2.7% year over year, below guidance pace. EPS declined in Q1, signaling margin pressure. Management cut guidance recently, showing risks to targets. Leadership changes may disrupt execution.
The stock trades about 22% above our fair value near $48, reflecting roughly 5% revenue growth expected by analysts. Our fair value is 10% below the Street median, suggesting some optimism is priced in. We see risks to meeting EPS and margin targets.
Breaks if: EPS falls below $1.85
Breaks if: No growth or decline in semiconductor and overseas orders
Breaks if: operating margin falls below 20%
Breaks if: annual revenue falls below $3.41 billion
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent revenue and earnings growth. The current thesis state is intact, supported by recent strong financial results and management's commitment to maintaining guidance.
The market appears to have priced in a stretched valuation compared to peers, with expectations for continued growth. There is a low fragility tier, indicating that the current setup is not overly sensitive to negative news.
Fundamentals are likely to show continued revenue and earnings growth, as management is on track to meet their guidance for FY2026. However, there is an elevated risk due to potential economic downturns that could impact performance.
The thesis hinges on management's ability to maintain guidance and the overall health of the healthcare sector. Key factors include the performance of sector bellwethers and the impact of macroeconomic conditions on demand.
In the next 1 to 3 years, BRKR's performance will depend on its execution against guidance and external economic factors. Not investment advice.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The company beat earnings expectations recently. It maintained its revenue and EPS guidance for FY2026. However, goodwill impairment raises concerns about future profitability. This mixed outlook reflects both strengths and challenges for the company.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.